Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 32Tumor-Agnostic 1Thoracic 1Head & Neck 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Salivary Gland Neoplasms 1

Interventions

Cisplatin 98pembrolizumab 79Radiotherapy 49Carboplatin 41Magnetic Resonance Spectroscopy 37toripalimab 34Radiotherapy, Intensity-Modulated 34Gemcitabine 29Docetaxel 28Cetuximab 28Specimen Handling 26Surgical Procedures, Operative 23Paclitaxel 23Fluorouracil 22Radiation 20Nivolumab 20Biopsy 18Drug Therapy 17Chemoradiotherapy 17Blood Specimen Collection 17Capecitabine 15Standard of Care 14tislelizumab 13Surveys and Questionnaires 13Platinum 13camrelizumab 12nimotuzumab 11Immune Checkpoint Inhibitors 11130-nm albumin-bound paclitaxel 111,2-diaminocyclohexaneplatinum II citrate 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × enfortumab vedotin × Head & Neck × Clear all
NCT06145308 2026-04-02

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Peking Union Medical College

Phase 2 Recruiting
39 enrolled
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡